Earlier this evening, President Trump announced the administration’s second Most-Favored-Nation (MFN) agreement with AstraZeneca to bring drug prices in line with the lowest paid by other developed nations (MFN pricing). The agreement mirrors that of Pfizer’s that was announced at the end of September (Impact summary) features the following: Providing every state Medicaid program access to MFN prices on AstraZeneca products; Ensuring that foreign… (Slifer, October 10, 2025) #Drug Pricing, #Prescription Drugs